Overview
Neuvasq Biotechnologies is pioneering the development of first-in-class Gpr124- and Reck-targeting Wnt surrogate antibodies, designed to restore the integrity of the blood-retina and blood-brain barriers. This approach targets vascular retinopathies such as diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), as well as severe neurological disorders.
In the news
- Heading to Cologne for BIO-Europe 2026 Our Executive Director Denis Bedoret will be attending #BIOEurope2026, from November 9–11, in Cologne, Germany. As we advance into our next stage of development, Denis looks forward to connecting with potential partners and investors to explore opportunities for collaboration. We look forward to discussing NVQ501 our bifunctional antibody designed for vascular retinopathies. It combines neurovascular barrier repair with VEGF inhibition, bringing together two complementary mechanisms in a
- This World Sight Day, we are focusing on the importance of protecting vision. As part of the International Agency for the Prevention of Blindness IAPB’s #LoveYourEyes campaign, we want to echo their call to make eye health a priority for everyone, everywhere. At Neuvasq, we are developing multispecific antibodies designed to restore blood-retina barrier integrity and address the vascular dysfunction underlying diseases such as diabetic macular edema. Today, we emphasize our commitment to advancing research that could help protect
- Neuvasq is heading to EURETINA 2026! From 1–4 October, our CSO Ralph Laufer and Head of Preclinical Research Sylvaine Guérit will join the retina community in Vienna to exchange on new approaches to treating diseases of the eye. To learn more about our latest advances in repairing the blood-retina barrier in conditions such as diabetic macular edema, where leaky retinal vessels can lead to fluid buildup and vision loss, join us for our oral presentation: 👩🔬Presenter: Sylvaine Guérit, Head of Preclinical Research 📄 Title:
- How can an engineered antibody mimic a natural signaling molecule? Wnt7 naturally activates Wnt/β-catenin signaling through a receptor complex that includes GPR124 and LRP6, helping maintain the integrity of CNS vascular barriers. Neuvasq’s multispecific antibodies follow the same principle by binding both receptors and activating this pathway in a nature-inspired manner. By harnessing the physiological role of Wnt signalling in vascular stability, our goal is to restore compromised barrier function, while preserving a favorable
- Today, we are proud to introduce Oya Yilmaz, an experienced Research Associate who has brought valuable scientific insights and hands-on expertise to Neuvasq’s drug discovery team for the past year and a half. 🌱 How does she contribute to the team? Oya focuses on developing and optimizing in vitro models to assess the potency and efficacy of our drug candidates. Her work helps us better understand how candidates perform and how different experimental parameters can influence the results. 💡 Which part of her work she enjoys most?
- After a productive summer, we are ready to reconnect with the scientific community! We look forward to attending the European Brain Barriers Meeting 2026 on September 16–18 in Aarhus, Denmark and sharing insights into our approach to restoring neurovascular integrity. Neuvasq’s first-in-class multispecific antibodies are designed to activate the Wnt/β-catenin pathway to selectively repair neurovascular barriers, with the potential to slow or prevent disease progression. We invite you to join our poster presentation and learn
- 𝐀𝐧𝐭𝐢-𝐕𝐄𝐆𝐅 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐚𝐫𝐞 𝐝𝐞𝐬𝐢𝐠𝐧𝐞𝐝 𝐭𝐨 𝐛𝐢𝐧𝐝 𝐚𝐧𝐝 𝐧𝐞𝐮𝐭𝐫𝐚𝐥𝐢𝐳𝐞 𝐕𝐄𝐆𝐅, 𝐚 𝐤𝐞𝐲 𝐟𝐚𝐜𝐭𝐨𝐫 𝐭𝐡𝐚𝐭 𝐢𝐬 𝐚𝐛𝐧𝐨𝐫𝐦𝐚𝐥𝐥𝐲 𝐞𝐥𝐞𝐯𝐚𝐭𝐞𝐝 𝐢𝐧 𝐃𝐌𝐄 𝐚𝐧𝐝 𝐰𝐞𝐭 𝐀𝐌𝐃. However, blood-retina barrier dysfunction involves multiple pathways and structural changes beyond VEGF alone. While anti-VEGF therapies can reduce leakage, they do not directly repair the damaged barrier itself. As a result, some patients experience incomplete or insufficiently durable responses, highlighting
- 𝐖𝐡𝐞𝐧 𝐭𝐡𝐞 𝐫𝐞𝐭𝐢𝐧𝐚 𝐢𝐬 𝐬𝐰𝐨𝐥𝐥𝐞𝐧 𝐚𝐧𝐝 𝐬𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐚𝐥𝐥𝐲 𝐝𝐢𝐬𝐫𝐮𝐩𝐭𝐞𝐝, 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐜𝐚𝐧 𝐬𝐮𝐟𝐟𝐞𝐫 𝐟𝐫𝐨𝐦 𝐛𝐥𝐮𝐫𝐫𝐞𝐝, 𝐝𝐢𝐬𝐭𝐨𝐫𝐭𝐞𝐝 𝐨𝐫 𝐝𝐢𝐦𝐦𝐞𝐝 𝐯𝐢𝐬𝐢𝐨𝐧. In diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD), breakdown of the blood-retina barrier allows fluid and other substances to leak into retinal tissue. This can result in retinal swelling, cysts formation and abnormal blood vessel growth. Left unchecked, these changes can
Something wrong or missing? Send an update. Fixed within 24 hours.